IL313785A - Discernible cell surface protein variants of cd45 for use in cell therapy - Google Patents

Discernible cell surface protein variants of cd45 for use in cell therapy

Info

Publication number
IL313785A
IL313785A IL313785A IL31378524A IL313785A IL 313785 A IL313785 A IL 313785A IL 313785 A IL313785 A IL 313785A IL 31378524 A IL31378524 A IL 31378524A IL 313785 A IL313785 A IL 313785A
Authority
IL
Israel
Prior art keywords
seq
cells
isoform
cell
amino acid
Prior art date
Application number
IL313785A
Other languages
English (en)
Hebrew (he)
Inventor
Urlinger Stefanie
Jeker Lukas
Lepore Rosalba
MATTER MARONE Romina
Camus Anna
SINOPOLI Alessandro
DURZYNSKA Izabela
Haydn Anna
DEVAUX Anna
GARAUDE Simon
Original Assignee
Universit?T Basel
Cimeio Therapeutics Ag
Urlinger Stefanie
Jeker Lukas
Lepore Rosalba
MATTER MARONE Romina
Camus Anna
SINOPOLI Alessandro
DURZYNSKA Izabela
Haydn Anna
DEVAUX Anna
GARAUDE Simon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universit?T Basel, Cimeio Therapeutics Ag, Urlinger Stefanie, Jeker Lukas, Lepore Rosalba, MATTER MARONE Romina, Camus Anna, SINOPOLI Alessandro, DURZYNSKA Izabela, Haydn Anna, DEVAUX Anna, GARAUDE Simon filed Critical Universit?T Basel
Publication of IL313785A publication Critical patent/IL313785A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70589—CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL313785A 2021-12-23 2022-12-23 Discernible cell surface protein variants of cd45 for use in cell therapy IL313785A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21217465 2021-12-23
PCT/EP2022/087829 WO2023118608A1 (en) 2021-12-23 2022-12-23 Discernible cell surface protein variants of cd45 for use in cell therapy

Publications (1)

Publication Number Publication Date
IL313785A true IL313785A (en) 2024-08-01

Family

ID=79171049

Family Applications (1)

Application Number Title Priority Date Filing Date
IL313785A IL313785A (en) 2021-12-23 2022-12-23 Discernible cell surface protein variants of cd45 for use in cell therapy

Country Status (10)

Country Link
EP (1) EP4452417A1 (enExample)
JP (1) JP2025500288A (enExample)
KR (1) KR20240119146A (enExample)
CN (1) CN118541158A (enExample)
AU (1) AU2022422572A1 (enExample)
CA (1) CA3240875A1 (enExample)
IL (1) IL313785A (enExample)
MX (1) MX2024007316A (enExample)
WO (1) WO2023118608A1 (enExample)
ZA (1) ZA202405124B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
WO2026082736A1 (en) * 2024-10-14 2026-04-23 Cimeio Therapeutics Ag Chimeric antigen receptor (car) that targets receptor-type tyrosine phosphatase c (cd45) and its use to related applications

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170226209A1 (en) 2014-08-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
WO2017155937A1 (en) 2016-03-07 2017-09-14 Actinium Pharmaceuticals, Inc. Stabilized radiolabeled anti-cd45 immunoglobulin compositions
US11499168B2 (en) 2016-04-25 2022-11-15 Universitat Basel Allele editing and applications thereof
CN109641051A (zh) 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
LT3535392T (lt) 2016-11-02 2024-04-25 Universität Basel Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje
RU2019130504A (ru) 2017-02-28 2021-03-30 Вор Байофарма, Инк. Композиции и способы ингибирования линиеспецифических белков
WO2019084273A1 (en) 2017-10-25 2019-05-02 Actinium Pharmaceuticals, Inc. METHODS OF ANTI-CD45-BASED LYMPHODEPPLICATION AND USES THEREOF IN COMBINATION WITH ACT-BASED ANTICANCER THERAPIES
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
CN109991410B (zh) 2017-12-29 2022-07-05 上海白泽医学检验所有限公司 一种含抗cd45单抗的组合物及其使用方法
WO2020018580A1 (en) 2018-07-16 2020-01-23 Fred Hutchinson Cancer Research Center Bispecific affinity reagent and related methods for pretargeted radioimmunotherapy against cd45+ cell
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
EP3877416A4 (en) 2018-10-30 2022-07-27 Magenta Therapeutics, Inc. ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF
WO2020092655A1 (en) * 2018-10-30 2020-05-07 Magenta Therapeutics, Inc. Methods for allogeneic hematopoietic stem cell transplantation
WO2020159656A1 (en) 2019-02-01 2020-08-06 Actinium Pharmaceuticals, Inc. Molecules and their derivatives directed against cd45
WO2020170254A1 (en) 2019-02-21 2020-08-27 Ramot At Tel-Aviv University Ltd. Treatment of diseases with multimeric peptides

Also Published As

Publication number Publication date
WO2023118608A1 (en) 2023-06-29
AU2022422572A1 (en) 2024-06-06
CA3240875A1 (en) 2023-06-29
JP2025500288A (ja) 2025-01-09
EP4452417A1 (en) 2024-10-30
KR20240119146A (ko) 2024-08-06
MX2024007316A (es) 2024-06-26
CN118541158A (zh) 2024-08-23
ZA202405124B (en) 2025-10-29

Similar Documents

Publication Publication Date Title
EP3221355B1 (en) Combination therapy of t cell activating bispecific antigen binding molecules cd3 and folate receptor 1 (folr1) and pd-1 axis binding antagonists
JP6865688B2 (ja) Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体
CN103476429B (zh) 新型调节剂及使用方法
JP2020182454A (ja) Ｃｄ１９に特異的な抗体およびキメラ抗原受容体
CN117616123B (zh) 抗ctla-4抗体
CN112912397A (zh) 抗cd3抗体及其用途
CN117545779B (zh) 抗ctla-4抗体的用途
US20250057951A1 (en) Discernible cell surface protein variants of cd117 for use in cell therapy
CN115397515A (zh) 人抗cd33抗体和其用途
US20240189424A1 (en) Engineered natural ligand-based car: directed evolution of the stress-receptor nkp30
IL313785A (en) Discernible cell surface protein variants of cd45 for use in cell therapy
US20250326818A1 (en) Discernible cell surface protein variants for use in cell therapy
AU2024243735A1 (en) Discernible cell surface protein variants of cd33 for use in cell therapy
CN118401558A (zh) 用于细胞疗法的cd117的可辨识细胞表面蛋白变体
WO2025031965A1 (en) Discernible cell surface protein variants of cd52 for use in cell therapy
CN120077071A (zh) 抗vista构建体及其用途
CN117813110A (zh) 用于在细胞治疗中使用的可辨别细胞表面蛋白变体
EA052414B1 (ru) Применение анти-ctla-4 антитела
EA049685B1 (ru) Таргетирующие dll3 мультиспецифические антигенсвязывающие молекулы и их применения
HK40052977A (en) Anti-cd3 antibodies and uses thereof